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20 Oral Presentationsand 13.2 cGy TBI. GVHD prophylaxis was with CSA/MMF.
Thirty two percent were transplanted with one UCB unit and
68% with two units. Disease status at the time of transplant in-
cluded: CR1 (46%), CR2 (45%), .CR2-relapse (9%). Sixty one
percent of patients are alive at a median follow up of 737 days
(range 44–2,322 days). Using survival tree and log rank analysis,
weekly ALCs were analyzed to determine an ALC cut-point which
gave two distinct groups based on transplant associated outcomes.
In multivariate analysis an ALC . 0.2  109/L at 4 weeks after
UCB transplant was associated with significantly better disease
free survival (DFS) (relative risk (RR) 5 0.158, 69% vs. 33%,
p 5 0.0005) and overall survival (OS) at 2 years (RR 5 0.125,
74% vs. 33%, p\0.0001). Similarly, at this same cut off (ALC .
0.2), patients were less likely to have treatment related mortality
(TRM) (RR 5 0.01, 7% vs. 67%, p\0.0001). For grade II-IV
aGVHD, multivariate analysis showed that an ALC . 0.4 (at 4
weeks post-transplant) was associated with less aGVHD at
D1100 (RR 5 0.057, 28% vs. 61%, p 5 0.0004). At 7 weeks after
transplant, patients with an ALC . 1.2 109/liter was associated
with a lower risk of relapse (univariate analysis 0% vs. 21%, p 5
0.026). We next sought to determine whether any factor predicted
better ALC recovery at four weeks post-UCB transplant. Multi-
variate analysis revealed that the only factor associated with
more rapid ALC recovery was the use of two umbilical cord blood
units. Double unit recipients had an ALC that was10.155 109/L
higher at 4 weeks compared to single unit recipients (p 5 0.039).
Collectively, these data suggest that ALC is a readily available
parameter for assessing risks for TRM, DFS, OS and relapse.
Rapid ALC recovery may explain the observed benefits with
double UCB transplant.LATE EFFECTS/QUALITY OF LIFE
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THE IMPACT OF FULL DOSE TOTAL BODY IRRADIATION(TBI)-CONTAIN-
ING CONDITIONING ON CHRONIC KIDNEY DISEASE AND THROMBOTIC
MICROANGIOPATHIC ANEMIA IN ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION(HSCT)
Glezerman, I.1, Jhaveri, K.2, Papadopouolos, E.B.1, Flombaum, C.1,
Jakubowski, A.A.1 1Memorial Sloan Kettering Cancer Center,
New York, NY; 2Weill Medical College of Cornell University, New
York, NY
Background: Chronic kidney disease (CKD) and thrombotic mi-
croangiopathy (TMA) are potential late post-transplant complica-
tions in survivors of HSCT. CKD and TMA can have a significant
impact on healthcare costs and quality of life. Both disorders have
been associated with calcineurin inhibitors (CNI), TBI, older age, fe-
male gender, and graft versus host disease (GVHD), however, the
contribution of each of these factors on development of CKD/
TMA has not been well defined. T-cell depletion (TCD) of allografts
as prophylaxis for GvHD has produced similar survival outcomes to
those of conventional HSCTs in appropriately selected patients and
can obviate the need for CNIs. The lack of CNI exposure offers
a unique opportunity to study the role of TBI in the development
of CKD/TMA.
Methods: Between 1/2001 and 1/2005, 102 adult patients re-
ceived TCD myeloablative HSCTs at MSKCC and met inclusion
criteria for this analysis which was approved by the IRB. Thirty-
two patients received a non-TBI containing regimen (group A) and
70 received TBI (1375 cGy without kidney shielding) with chemo-
therapy (group B). Baseline and followup data were collected by a ret-
rospective review of medical records. Renal function (estimated
glomerular filtration rate [GFR]) was calculated using the Modified
Diet in Renal Disease extended equation. TMA was diagnosed by
kidney biopsy or by identification of multiple components of the
clinical syndrome.
Results: Median followup for both groups was 21 months. Results
and incidence of CKD and TMA are summarized below. Of note,
pretransplant GFR was lower in group A vs B (p\0.006). Incidence
of CKD, TMA, and HTN was significantly higher in those patients
receiving TBI (group B).Conclusions: The data demonstrate a strong correlation between
the use of TBI, in the absence of CNIs, and the development of post-
transplant CKD and TMA, suggesting the need for clinical trials to
prevent these complications when using TBI.Group A Group B P\Pre-treatment GFR1 (mean) 87.1 (SD525.6) 102.3 (SD523.9) 0.006
GFR at 6 months (mean) 72.3 (SD521.9) 74.8 (SD522.6) NS (0.6)
GFR at 12 months (mean) 67.2 (SD514.1) 61.6 (SD519.8) NS (0.13)
GFR at 18 months (mean) 67.9 (SD510.2) 59.8 (SD520.5) 0.02
GFR at 24 months (mean) 68.3 (SD512.3) 60.5 (SD522.0) 0.05
TMA2 0 (0%) 11 (15.7%) 0.016
HTN3 2 (6.3%) 18 (25.7%) 0.02
GFR\30 at 24 months 0 (0%) 6 (10.9%) 0.171Glomerular filtration rate.
2Thombotic microangiopathic anemia.
3Hypertension.48
RELAPSE AND MORTALITY IN YOUNG SURVIVORS 2.5 YEARS AFTER AU-
TOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR SOLID ORGAN TUMORS AND MALIGNANT BLOOD
DISORDERS
Hutspardol, S., Shaw, P.J. The Children’s Hospital AtWestmead, Sydney,
New South Wales, Australia
We studied the mortality, relapse and transplant-related compli-
cations of 331 patients (age 6 month–19 years at transplant, median
8 years) with solid organ tumors (91 soft-tissue tumor and 18 brain
tumor) and malignant blood disorders (200 leukemia and 22
lymphoma) after a bone marrow (n 5 265), peripheral blood (n 5
56), and cord blood (n 5 10) hematopoietic stem cell transplant
(HSCT). One hundred and forty-six patients remained relapse-free
for 2.5 or more years after HSCT. Of these, 132 (90%) were alive
at a median follow up time of 10 years (range; 2.5–27.0). Four
(2.7%) relapsed between 2.7 and 13.4 years (median 6.1) after trans-
plant. No patients with hematologic malignancies relapsed after 2.5
years of HSCT. Six patients (4.1%) died of complications related to
the transplant: 3 from chronic pulmonary graft-versus-host disease
and 1 each from presumed busulphan-induced chronic obstructive
lung disease, cardiomyopathy, and non-GVHD interstitial
pulmonary fibrosis. Three patients (2.1%) developed T-cell ALL,
rhabdomyosarcoma and astrocytoma as second malignancies. For
the external cause of death, one died from drug overdose at 5 years
after the transplant. The 5- and 10-year probabilities of overall sur-
vival (from the 2.5-year mark) are 95% and 93% and the 5- and 10-
year probabilities of relapse free survival (from the 2.5-year mark) are
98% and 95%. In multivariate analysis, peripheral blood stem cell
(PBSC) as the source of stem cells and older age at HSCT unfavor-
ably influenced the overall survival. Gender, age at HSCT, type of
malignant disease, low or high risk category for relapse, stem cell
source and TBI were not found to be predictive for relapse free sur-
vival. In conclusion, for young patients with malignancies who were
relapse free 2.5 years after HSCT, the probability of cure was very
high and the long term survival was excellent. Chronic pulmonary
GVHD was the leading cause of late death. Toxicity related to
high intensity chemotherapy and TBI potentially resulted to the
lung toxicity and death in long term survivors.49
MEASURING THE SYMPTOM BURDEN OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH AND WITHOUT
ACUTE GRAFT-VERSUS-HOST DISEASE
Williams, L.A.1, Giralt, S.A.2, Wang, X.S.1, Mobley, G.M.1,
Mendoza, T.R.1, Cohen, M.Z.3, Cleeland, C.S.1 1The University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2The University of Texas
M.D. Anderson Cancer Center, Houston, TX; 3University of Nebraska
Medical Center, Omaha, NE
Significance: Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is an intensive but potentially curative therapy for
patients with life-threatening illnesses. During alloHSCT, patients
Oral Presentations 21develop symptom burden that substantially interferes with daily ac-
tivities. Acute graft-versus-host disease (aGVHD) may significantly
contribute to symptom burden.
Theoretical Framework: Symptom burden is the combined
impact of all symptoms on one’s ability to function as one did before
onset of disease and therapy.
Problem and Purpose: Symptom burden cannot be managed if it
is not reliably and sensitively measured over time. The purpose of
this study was to determine the reliability and sensitivity of the M.
D. Anderson Symptom Inventory (MDASI), a brief self-report
measure of the severity and impact of cancer-related symptoms, in
patients with and without aGVHD.
Methods: This is a retrospective analysis of a combined dataset of
125 patients who had completed multiple assessments using the
MDASI during the first 3 months following alloHSCT. Symptom bur-
den was measured using the area under the curve (AUC) of mean symp-
tom severity scores from day of HSCT to 3 months after HSCT.
Results: Sample demographic, disease, and HSCT characteristics
and mean and standard deviations (SD) of symptom severity at 3 time
points are in shown Table 1. The MDASI symptom items had
a reliability index (Cronbach alpha) of 0.892. The MDASI symptom
items were sensitive enough to detect a significant difference in the
AUC of symptom severity from the day of HSCT to 3 months after
HSCT (p 5 0.025) and from 22 days to 3 months after HSCT (p 5
0.031) between patients with and without aGVHD.
Implications: The difference in symptom burden between
patients with and without aGVHD was not significant from the
day of HSCT to 22 days after HSCT. We had predicted that the dif-
ference would not be significant between the 2 groups during this
time period, as symptoms during this time are caused mainly by
the preparative regimen. We had predicted that the difference in
symptom severity would be greater between patients with and with-
out aGHVD between 22 and 100 days after HSCT. By Day 22, many
patients will have engrafted and aGVHD will begin to develop and
increase symptom burden. The MDASI is an easily-completed and
reliable measure of symptom burden in patients undergoing
alloHSCT and is sensitive enough to detect differences in symptom
burden between patients with and without aGVHD.
Table 1. Demographic/Treatment Characteristics and Symp-
tom Severity Means
N5125 N %Sex - Male 67 53.6%
Race - White, non-Hispanic 85 68.0%
Diagnosis
Acute leukemia/MDS 77 61.6%
Chronic leukemia 19 15.2%
Lymphoma 22 17.6%
Other 7 5.6%Type of HSCT
Related donor 94 75.2%
Unrelated donor 31 24.8%Maximum Grade of aGVHD
None 54 43.2%
1 35 28.0%
2 19 15.2%
3 17 13.6%
4 0 0Mean SD1Age 41.12 12.95
Highest Grade of
School Completed14.68 2.06No aGVHD aGVHD No aGVHD aGVHD
Mean Symptom
Severity Score - Day
of HSCT22.80 2.63 1.82 1.88Mean Symptom
Severity Score - Day 2222.21 2.66 1.78 1.87Mean Symptom
Severity Score - 3 Months21.43 2.36 1.35 1.791SD 5 standard deviation.
2Symptom severity: 0 to 10 scale, 05 not present 105 as bad as you can
imagine.LEUKEMIA
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IMPACT OF CYTOGENETICS RISK ON OUTCOME AFTER REDUCED INTEN-
SITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLO-SCT) FROM AN HLA IDENTICAL SIBLING FOR PATIENTS WITH
ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION
(CR1)
Mohty, M., Labopin, M., Milpied, N., Cornelissen, J.J., Blaise, D.,
Petersen, E., Theorin, N., Goker, H., Socie, G., Rocha, V., for the Acute
Leukemia Working Party of EBMT, Paris, France
The relatively higher risk of relapse after RIC allo-SCT, and con-
tinuous improvements in non-allo-SCT strategies, raise concern
about the utility of this approach in AML patients in CR1 (e.g. in
comparison to intensive chemotherapy and new drugs). Thus far,
no large studies have yet assessed the impact of cytogenetics risk on
outcome after RIC allo-SCT. This report describes the results of
378 AML patients transplanted in CR1 using a RIC regimen and re-
ported to the EBMT registry between 2000 and 2007, and for whom
detailed cytogenetics data were available. All patients received RIC
allo-SCT from an HLA identical sibling. RIC was defined as Busulfan
conditioning regimens containing\ 8mg/kg total dose, or TBI\6
Gy: The median age was 55 (range, 18–74) y. The median intervals
from AML diagnosis to CR1 and from CR1 to RIC allo-SCT were
45 and 155 days respectively. In this series, 21 patients (6%) were in
the good cytogenetics risk group, while 304 patients (80%) and 53 pa-
tients (14%) belonged to the intermediate and poor cytogenetics risk
groups respectively. Age, year of transplant, WBC at diagnosis, gen-
der, CMV serostatus, stem cell source, and RIC regimen type were
comparable between all three groups. The M5-6-7 FAB subgroup
was significantly higher in the poor risk group (30% vs. 20% in the
intermediate group). With a median follow-up of 24 (range, 1–93)
months, the KM estimates of 2 years leukemia-free survival (LFS)
were 6464, 5763 and 3867% in the good-, intermediate-, and
poor-risk subgroups respectively (P 5 0.003). In multivariate analy-
sis, cytogenetics was not significantly associated with non-relapse
mortality. However, relapse incidence was significantly influenced
by the cytogenetics risk groups (P5 0.0001) and a higher WBC at di-
agnosis (P5 0.001). Finally, LFS was significantly influenced by the
cytogenetics risk groups (P5 0.004), a higher WBC at diagnosis (P5
0.006), and year of transplant (P 5 0.04). These results suggest that
RIC allo-SCT from an HLA-matched sibling donor is a valid option
for AML patients in CR1 not eligible for standard allo-SCT. As it has
been shown in the setting of myeloablative conditioning allo-SCT,
patients from the poor cytogenetics risk group had increased relapse
incidence and decreased LFS rate after RIC allo-SCT. Therefore,
prospective strategies such as use of new drugs, intensification of
conditioning regimen, post-transplant immunotherapy should be
investigate to improve current results in this group.51
RISKS AND BENEFITS OF UNRELATED DONOR PERIPHERAL BLOOD PRO-
GENITOR CELL S (PBSC) IN CHILDREN AND ADOLESCENTS WITH ACUTE
LEUKEMIA
Ringden, O.1, Eapen, M.2, Locatelli, F.3, Champlin, R.E.4,
Frangoul, H.A.5, Remberger, M.1, Gee, A.P.6, Laughlin, M.J.7,
Rocha, V.8 1Karolinska Institutet, Stockholm, Sweden; 2Medical College
of Wisconsin, Milwaukee, WI; 3 IRCCS Policlinico San Matteo, Pavia,
Italy; 4University of Texas, Houston, TX; 5Vanderbilt University, Nash-
ville, TN; 6Baylor College of Medicine, Houston, TX; 7Case Western
Reserve University, Cleveland, OH; 8Hopital Saint Louis, Paris, France
PBPC is an acceptable alternative to bone marrow (BM) for trans-
planting children with leukemia. Children and adolescents with leu-
kemia receiving PBSC compared to BM from HLA-identical sibling
donors had more chronic graft-vs-host disease (GVHD), higher
transplant-related mortality (TRM) and lower leukemia-free survival
(LFS). We wanted to find out if children receiving unrelated donor
grafts should be given BM rather than PBPC. Therefore, we com-
pared the results of 385 unrelated donor BM transplants that were
allele-matched (n 5 186) or mismatched (n 5 199) at HLA A, B,
C, DRß1 and 110 PBPC transplants that were matched (n 5 60)
or mismatched (n 5 50) at HLA A, B, C, DRß1 in patients younger
